Search

Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.

… Thursday, December 7, 2017 Summary A new analysis finds that certain genes people are born with may play a critical role in whether or not checkpoint inhibitors will work. For some people with cancer, immunotherapy drugs called checkpoint inhibitors , which take the brakes off the immune system and allow

Immunotherapy drugs called checkpoint inhibitors are effective against many cancers, including kidney cancer. Learn how these drugs are used to treat both early- and late-stage disease.

… Monday, September 12, 2022 In an effort to improve the prognosis (outcomes) for kidney cancer , more patients are receiving immunotherapy , which activates the body’s own immune system to kill cancerous cells. Here, genitourinary medical oncologist Robert Motzer from Memorial Sloan Kettering Cancer Center

The third-annual Crain’s New York Business Notable in Healthcare list celebrates outstanding individuals in the healthcare community within the New York metropolitan area, and honors their professional, civic, and philanthropic achievements.

… Monday, August 10, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Physician-in-Chief and Chief Medical Officer Lisa M. DeAngelis, MD , and Community Outreach Manager Julia Ramirez, MA , are included on the Crain’s New York Business 2020 Notable in Healthcare list. The list celebrates outstanding

The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop.

… Tuesday, April 8, 2014 Summary The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop. This image, generated in the lab of molecular biologist Prasad Jallepalli , shows a human cell nucleus — a membrane-enclosed compartment within

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

… Tuesday, December 13, 2011 Summary Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers. A Memorial Sloan Kettering study suggests that in the future, researchers might be able

Twelve students successfully defended their dissertations and received their PhD degrees at Commencement on May 19.

… Monday, May 23, 2016 Twelve students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 37th annual academic convocation on May 19, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, in San Diego, California.

… Tuesday, April 14, 2026 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026